Iksuda licenses novel protein-alkylating, tumour-activated pro-drug payload series to develop ADCs with enhanced therapeutic index Development…
Iksuda licenses novel protein-alkylating, tumour-activated pro-drug payload series to develop ADCs with enhanced therapeutic index Development…